PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
29558203-9	2018	Increasing adenosine levels, as well as stimulating the adenosine receptors A2A and A2B, exhibited strong prodegenerative effects, whereas conversely, lowering adenosine levels by inhibition of CD73 resulted in protective effects against degeneration.	Adenosine	56-65	immunoglobulin kappa variable 2D-29	Homo sapiens	76-87
29857029-4	2018	At cellular level, Rhes interferes with adenosine A2A- and dopamine D1 receptor-dependent cAMP/PKA pathway, upstream of the activation of the heterotrimeric G protein complex.	Cyclic AMP	90-94	immunoglobulin kappa variable 2D-29	Homo sapiens	50-79
29880250-0	2018	Identification of novel thiazolo[5,4-d]pyrimidine derivatives as human A1 and A2A adenosine receptor antagonists/inverse agonists.	Thiazolo[5,4-d]pyrimidine	24-49	immunoglobulin kappa variable 2D-29	Homo sapiens	78-81
30044380-0	2018	Comparative Study of Carborane- and Phenyl-Modified Adenosine Derivatives as Ligands for the A2A and A3 Adenosine Receptors Based on a Rigid in Silico Docking and Radioligand Replacement Assay.	carborane	21-30	immunoglobulin kappa variable 2D-29	Homo sapiens	93-96
30044380-0	2018	Comparative Study of Carborane- and Phenyl-Modified Adenosine Derivatives as Ligands for the A2A and A3 Adenosine Receptors Based on a Rigid in Silico Docking and Radioligand Replacement Assay.	Adenosine	52-61	immunoglobulin kappa variable 2D-29	Homo sapiens	93-96
29533161-1	2018	OBJECTIVE: Polydeoxyribonucleotide as adenosine receptor (A2A) agonist has been used in plastic surgery and dermatology related to its regenerative property.	Polydeoxyribonucleotides	11-34	immunoglobulin kappa variable 2D-29	Homo sapiens	58-61
27915051-2	2017	This review makes the point that caffeine is - in low doses - an antagonist of adenosine acting at A1, A2A and A2B receptors.	Caffeine	33-41	immunoglobulin kappa variable 2D-29	Homo sapiens	103-106
28114825-0	2017	The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles.	7-aminopyrazolo(4,3-d)pyrimidine	64-96	immunoglobulin kappa variable 2D-29	Homo sapiens	132-135
28114825-1	2017	New 7-amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives, substituted at the 5-position with aryl(alkyl)amino- and 4-substituted-piperazin-1-yl- moieties, were synthesized with the aim of targeting human (h) adenosine A1 and/or A2A receptor subtypes.	7-amino-2-phenylpyrazolo[4,3-d]pyrimidine	4-45	immunoglobulin kappa variable 2D-29	Homo sapiens	229-232
28734062-4	2018	Therefore, a series of 3-phenylcarboxamidocoumarins were synthesized and their affinity for the human AR subtypes was screened by radioligand binding assays for A1 , A2A and A3 receptors and for A2B by adenylyl cyclase assay.	3-phenylcarboxamidocoumarins	23-51	immunoglobulin kappa variable 2D-29	Homo sapiens	166-169
27915051-2	2017	This review makes the point that caffeine is - in low doses - an antagonist of adenosine acting at A1, A2A and A2B receptors.	Adenosine	79-88	immunoglobulin kappa variable 2D-29	Homo sapiens	103-106
26796668-5	2016	Using extensive multiscale computer modelling, we find a marked propensity of DHA for interaction with both A2A and D2 receptors, which leads to an increased rate of receptor oligomerisation.	Docosahexaenoic Acids	78-81	immunoglobulin kappa variable 2D-29	Homo sapiens	108-118
27216633-0	2016	Discovery of potent adenosine A2a antagonists as potential anti-Parkinson disease agents.	Adenosine	20-29	immunoglobulin kappa variable 2D-29	Homo sapiens	30-33
27216633-3	2016	In this study, we combined extensive pharmacophore modeling and quantitative structure-activity relationship (QSAR) analysis to explore the structural requirements for potent Adenosine A2A antagonists.	Adenosine	175-184	immunoglobulin kappa variable 2D-29	Homo sapiens	185-188
27216633-6	2016	Best QSAR models and their associated pharmacophore hypotheses were validated by identification of several novel Adenosine A2A antagonist leads retrieved from the National Cancer Institute (NCI) structural database.	Adenosine	113-122	immunoglobulin kappa variable 2D-29	Homo sapiens	123-126
27161878-0	2016	Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors.	pyrazolo[4,3-d]pyrimidin-7-amino	40-72	immunoglobulin kappa variable 2D-29	Homo sapiens	105-108
27161878-4	2016	In particular, the 2-(2-methoxybenzyl)-5-(5-methylfuran-2-yl) derivative 25 possessed the highest hA2A and hA1 AR affinities (Ki=3.62nM and 18nM, respectively) and behaved as potent antagonist at both these receptors (cAMP assays).	2-(2-methoxybenzyl)-5-(5-methylfuran-2-yl	19-60	immunoglobulin kappa variable 2D-29	Homo sapiens	98-102
27161878-4	2016	In particular, the 2-(2-methoxybenzyl)-5-(5-methylfuran-2-yl) derivative 25 possessed the highest hA2A and hA1 AR affinities (Ki=3.62nM and 18nM, respectively) and behaved as potent antagonist at both these receptors (cAMP assays).	Cyclic AMP	218-222	immunoglobulin kappa variable 2D-29	Homo sapiens	98-102
27161878-5	2016	Its 2-(2-hydroxybenzyl) analog 26 also showed a high affinity for the hA2A AR (Ki=5.26nM) and was 22-fold selective versus the hA1 subtype.	hydroxybenzyl	9-22	immunoglobulin kappa variable 2D-29	Homo sapiens	70-74
26873265-0	2016	Pharmacophore generation, atom-based 3D-QSAR, HQSAR and activity cliff analyses of benzothiazine and deazaxanthine derivatives as dual A2A antagonists/MAO-B inhibitors.	benzothiazine	83-96	immunoglobulin kappa variable 2D-29	Homo sapiens	135-138
26873265-0	2016	Pharmacophore generation, atom-based 3D-QSAR, HQSAR and activity cliff analyses of benzothiazine and deazaxanthine derivatives as dual A2A antagonists/MAO-B inhibitors.	7-deazaxanthine	101-114	immunoglobulin kappa variable 2D-29	Homo sapiens	135-138
26796668-6	2016	Bioluminescence resonance energy transfer (BRET) experiments performed on living cells suggest that this DHA effect on the oligomerisation of A2A and D2 receptors is purely kinetic.	Docosahexaenoic Acids	105-108	immunoglobulin kappa variable 2D-29	Homo sapiens	142-152
25770019-2	2015	The aim of this study was to assess the expression of CD73 and A2A in immune cells and the effect of activation of A2A by an adenosine analogue on apoptosis in patients with obesity and type 2 diabetes mellitus (T2D).	Adenosine	125-134	immunoglobulin kappa variable 2D-29	Homo sapiens	115-118
25384972-0	2015	Human monocyte recognition of adenosine-based cyclic dinucleotides unveils the A2a Galphas protein-coupled receptor tonic inhibition of mitochondrially induced cell death.	adenosine-based cyclic dinucleotides	30-66	immunoglobulin kappa variable 2D-29	Homo sapiens	79-82
25384972-6	2015	The blockade of basal (adenosine-free) signaling from A2a inhibits protein kinase A (PKA) activity, thereby recruiting cytosolic p53, which opens the mitochondrial permeability transition pore and impairs mitochondrial respiration, resulting in apoptosis.	Adenosine	23-32	immunoglobulin kappa variable 2D-29	Homo sapiens	54-57
25384972-9	2015	Treatment with cyclic di-AMP selectively depleted A2a-expressing monocytes and their precursors via apoptosis.	cyclic diadenosine phosphate	15-28	immunoglobulin kappa variable 2D-29	Homo sapiens	50-53
25384972-10	2015	Thus, monocyte recognition of cyclic dinucleotides unravels a novel proapoptotic pathway: the A2a Galphas protein-coupled receptor (GPCR)-driven tonic inhibitory signaling of mitochondrion-induced cell death.	cyclic dinucleotides	30-50	immunoglobulin kappa variable 2D-29	Homo sapiens	94-97
25175458-6	2014	Special emphasis is given to in vivo microdialysis findings demonstrating the functional role putative A2A/D2 heteromers on striato-pallidal GABA neurons play in the modulation of this pathway, in which A2A receptors inhibit D2 receptor signaling.	gamma-Aminobutyric Acid	141-145	immunoglobulin kappa variable 2D-29	Homo sapiens	103-109
25393959-10	2014	In addition, SQ22536 (an adenylate cyclase inhibitor) and ZM241385 (a potent adenosine receptor A2A antagonist) attenuated the effect of adenosine on platelet aggregation induced by ADP and intraplatelet level of cAMP.	ZM 241385	58-66	immunoglobulin kappa variable 2D-29	Homo sapiens	96-99
25393959-10	2014	In addition, SQ22536 (an adenylate cyclase inhibitor) and ZM241385 (a potent adenosine receptor A2A antagonist) attenuated the effect of adenosine on platelet aggregation induced by ADP and intraplatelet level of cAMP.	Adenosine	77-86	immunoglobulin kappa variable 2D-29	Homo sapiens	96-99
25393959-10	2014	In addition, SQ22536 (an adenylate cyclase inhibitor) and ZM241385 (a potent adenosine receptor A2A antagonist) attenuated the effect of adenosine on platelet aggregation induced by ADP and intraplatelet level of cAMP.	Adenosine Diphosphate	182-185	immunoglobulin kappa variable 2D-29	Homo sapiens	96-99
25393959-13	2014	Docking of adenosine and inosine inside A2A showed that the main difference is the formation by adenosine of an additional hydrogen bond between the NH2 of the adenine group and the residues Asn253 in H6 and Glu169 in EL2 of the A2A receptor.	Adenosine	11-20	immunoglobulin kappa variable 2D-29	Homo sapiens	40-43
25393959-13	2014	Docking of adenosine and inosine inside A2A showed that the main difference is the formation by adenosine of an additional hydrogen bond between the NH2 of the adenine group and the residues Asn253 in H6 and Glu169 in EL2 of the A2A receptor.	Adenosine	11-20	immunoglobulin kappa variable 2D-29	Homo sapiens	229-232
25393959-13	2014	Docking of adenosine and inosine inside A2A showed that the main difference is the formation by adenosine of an additional hydrogen bond between the NH2 of the adenine group and the residues Asn253 in H6 and Glu169 in EL2 of the A2A receptor.	Inosine	25-32	immunoglobulin kappa variable 2D-29	Homo sapiens	40-43
25393959-13	2014	Docking of adenosine and inosine inside A2A showed that the main difference is the formation by adenosine of an additional hydrogen bond between the NH2 of the adenine group and the residues Asn253 in H6 and Glu169 in EL2 of the A2A receptor.	Inosine	25-32	immunoglobulin kappa variable 2D-29	Homo sapiens	229-232
25393959-13	2014	Docking of adenosine and inosine inside A2A showed that the main difference is the formation by adenosine of an additional hydrogen bond between the NH2 of the adenine group and the residues Asn253 in H6 and Glu169 in EL2 of the A2A receptor.	Adenosine	96-105	immunoglobulin kappa variable 2D-29	Homo sapiens	40-43
25393959-13	2014	Docking of adenosine and inosine inside A2A showed that the main difference is the formation by adenosine of an additional hydrogen bond between the NH2 of the adenine group and the residues Asn253 in H6 and Glu169 in EL2 of the A2A receptor.	Adenosine	96-105	immunoglobulin kappa variable 2D-29	Homo sapiens	229-232
25393959-13	2014	Docking of adenosine and inosine inside A2A showed that the main difference is the formation by adenosine of an additional hydrogen bond between the NH2 of the adenine group and the residues Asn253 in H6 and Glu169 in EL2 of the A2A receptor.	Hydrogen	123-131	immunoglobulin kappa variable 2D-29	Homo sapiens	40-43
25393959-13	2014	Docking of adenosine and inosine inside A2A showed that the main difference is the formation by adenosine of an additional hydrogen bond between the NH2 of the adenine group and the residues Asn253 in H6 and Glu169 in EL2 of the A2A receptor.	Hydrogen	123-131	immunoglobulin kappa variable 2D-29	Homo sapiens	229-232
25393959-13	2014	Docking of adenosine and inosine inside A2A showed that the main difference is the formation by adenosine of an additional hydrogen bond between the NH2 of the adenine group and the residues Asn253 in H6 and Glu169 in EL2 of the A2A receptor.	Adenine	160-167	immunoglobulin kappa variable 2D-29	Homo sapiens	40-43
25393959-13	2014	Docking of adenosine and inosine inside A2A showed that the main difference is the formation by adenosine of an additional hydrogen bond between the NH2 of the adenine group and the residues Asn253 in H6 and Glu169 in EL2 of the A2A receptor.	Adenine	160-167	immunoglobulin kappa variable 2D-29	Homo sapiens	229-232
24652540-0	2014	Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors.	Cyclic AMP	41-45	immunoglobulin kappa variable 2D-29	Homo sapiens	54-57
24652540-8	2014	The effects of extracellular cAMP on monocytes are mediated by CD73 ecto-5"-nucleotidase and A2A and A2B adenosine receptors, as selective antagonists could reverse its effects.	Cyclic AMP	29-33	immunoglobulin kappa variable 2D-29	Homo sapiens	93-96
24595664-16	2014	We conclude that (a) A1AR is unnecessary for LAD2 degranulation or AR enhancement; (b) A2A, A2B, and A3 ARs all contribute to pharmacologic AR enhancement of LAD2 and BMMC degranulation; and (c) LAD2 cells depend on microenvironmental adenosine to trigger AR modulation.	Adenosine	235-244	immunoglobulin kappa variable 2D-29	Homo sapiens	87-90
24483158-2	2014	Polydeoxyribonucleotide (PDRN), an adenosine A2A receptor agonist, improves wound healing in diabetic mice.	Polydeoxyribonucleotides	0-23	immunoglobulin kappa variable 2D-29	Homo sapiens	45-48
24024783-3	2014	Adenosine acts via specific GPCRs to either stimulate cyclic AMP formation, as exemplified by Gs -protein-coupled adenosine receptors (A2A and A2B ), or inhibit AC activity, in the case of Gi/o -coupled adenosine receptors (A1 and A3 ).	Adenosine	0-9	immunoglobulin kappa variable 2D-29	Homo sapiens	135-146
23917951-6	2013	Thus adenosine A2A antagonists, safinamide, and the antiepileptic agent zonisamide can extend the duration of action of levodopa.	Adenosine	5-14	immunoglobulin kappa variable 2D-29	Homo sapiens	15-18
23917951-6	2013	Thus adenosine A2A antagonists, safinamide, and the antiepileptic agent zonisamide can extend the duration of action of levodopa.	Levodopa	120-128	immunoglobulin kappa variable 2D-29	Homo sapiens	15-18
23917951-11	2013	Noradrenergic alpha2A antagonism using fipamezole can potentially reduce dyskinesia.	fipamezole	39-49	immunoglobulin kappa variable 2D-29	Homo sapiens	14-21
23741498-6	2013	A2A and A3ARs were able to modulate cAMP production and cell proliferation.	Cyclic AMP	36-40	immunoglobulin kappa variable 2D-29	Homo sapiens	0-3
23699177-0	2013	Protective effects of pentoxifylline in pulmonary inflammation are adenosine receptor A2A dependent.	Pentoxifylline	22-36	immunoglobulin kappa variable 2D-29	Homo sapiens	86-89
23699177-4	2013	Therefore, we studied the association between A2A and PTX in a murine model of LPS-induced pulmonary inflammation.	Pentoxifylline	54-57	immunoglobulin kappa variable 2D-29	Homo sapiens	46-49
23699177-9	2013	Further, oxidative burst of human PMNs was A2A-dependently reduced by 53% after PTX treatment.	Pentoxifylline	80-83	immunoglobulin kappa variable 2D-29	Homo sapiens	43-46
23699177-10	2013	In summary, PTX exhibits its anti-inflammatory effects in LPS-induced lung injury through an A2A-dependent pathway.	Pentoxifylline	12-15	immunoglobulin kappa variable 2D-29	Homo sapiens	93-96
23631427-5	2013	The best derivative was N-(4-oxo-4H-3,1-benzothiazin-2-yl)-4-phenylbutanamide (17, Ki human A2A, 39.5 nM; IC50 human MAO-B, 34.9 nM; selective versus other AR subtypes and MAO-A), which inhibited A2AAR-induced cAMP accumulation and showed competitive, reversible MAO-B inhibition.	N-(4-oxo-4H-3,1-benzothiazin-2-yl)-4-phenylbutanamide	24-77	immunoglobulin kappa variable 2D-29	Homo sapiens	92-95
23631427-5	2013	The best derivative was N-(4-oxo-4H-3,1-benzothiazin-2-yl)-4-phenylbutanamide (17, Ki human A2A, 39.5 nM; IC50 human MAO-B, 34.9 nM; selective versus other AR subtypes and MAO-A), which inhibited A2AAR-induced cAMP accumulation and showed competitive, reversible MAO-B inhibition.	Cyclic AMP	210-214	immunoglobulin kappa variable 2D-29	Homo sapiens	92-95
23741498-8	2013	In human chondrocyte and osteoblast cell lines, the inhibitory effect of A2A and A3AR stimulation on the release of prostaglandin E2 (PGE2), an important lipid inflammatory mediator, was observed.	Dinoprostone	116-132	immunoglobulin kappa variable 2D-29	Homo sapiens	73-76
23741498-8	2013	In human chondrocyte and osteoblast cell lines, the inhibitory effect of A2A and A3AR stimulation on the release of prostaglandin E2 (PGE2), an important lipid inflammatory mediator, was observed.	Dinoprostone	134-138	immunoglobulin kappa variable 2D-29	Homo sapiens	73-76
22474168-4	2012	Unexpectedly, A2A and beta2AR agonists also synergize with melphalan, lenalidomide, bortezomib, and doxorubicin.	Melphalan	59-68	immunoglobulin kappa variable 2D-29	Homo sapiens	14-17
20087854-5	2010	The endocannabinoid system is involved in the psychoactive effects of many compounds, and adenosine A2A receptors (the main receptor target of caffeine) elicit a permissive effect towards CB1 receptors, thus suggesting that A2A-CB1 receptor interaction plays a major role in the generation and maintenance of caffeine reinforcing behavior.	Caffeine	143-151	immunoglobulin kappa variable 2D-29	Homo sapiens	224-231
22474168-4	2012	Unexpectedly, A2A and beta2AR agonists also synergize with melphalan, lenalidomide, bortezomib, and doxorubicin.	Lenalidomide	70-82	immunoglobulin kappa variable 2D-29	Homo sapiens	14-17
22474168-4	2012	Unexpectedly, A2A and beta2AR agonists also synergize with melphalan, lenalidomide, bortezomib, and doxorubicin.	Bortezomib	84-94	immunoglobulin kappa variable 2D-29	Homo sapiens	14-17
22474168-4	2012	Unexpectedly, A2A and beta2AR agonists also synergize with melphalan, lenalidomide, bortezomib, and doxorubicin.	Doxorubicin	100-111	immunoglobulin kappa variable 2D-29	Homo sapiens	14-17
22142423-0	2012	Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A2A and A3 adenosine receptor ligands.	Adenosine	68-77	immunoglobulin kappa variable 2D-29	Homo sapiens	105-108
22033526-6	2012	Putative physical and functional interactions between the A2A and cannabinoid receptors were respectively assessed by co-immuno-precipitation and co-incubating the cells with the unselective cannabinoid agonist WIN55,212-2, and the selective A2A antagonist ZM-241385.	win55	211-216	immunoglobulin kappa variable 2D-29	Homo sapiens	58-61
22033526-6	2012	Putative physical and functional interactions between the A2A and cannabinoid receptors were respectively assessed by co-immuno-precipitation and co-incubating the cells with the unselective cannabinoid agonist WIN55,212-2, and the selective A2A antagonist ZM-241385.	ZM 241385	257-266	immunoglobulin kappa variable 2D-29	Homo sapiens	58-61
20087854-5	2010	The endocannabinoid system is involved in the psychoactive effects of many compounds, and adenosine A2A receptors (the main receptor target of caffeine) elicit a permissive effect towards CB1 receptors, thus suggesting that A2A-CB1 receptor interaction plays a major role in the generation and maintenance of caffeine reinforcing behavior.	Caffeine	309-317	immunoglobulin kappa variable 2D-29	Homo sapiens	224-231
19652957-11	2009	Since A2A, D2, and CB1 receptors coexpress on brain GABAergic neurons and reductions in markers of GABA neurotransmission have been identified in schizophrenia, a lower density of CB1 receptor induced by antipsychotics could represent an adaptative mechanism that reduces the endocannabinoid-mediated suppression of GABA release, contributing to the normalization of cognitive functions in the disorder.	gamma-Aminobutyric Acid	52-56	immunoglobulin kappa variable 2D-29	Homo sapiens	6-9
21309106-3	2010	Additionally, findings on the adenosine receptor 2A (A2A) gene, which has been reported to be associated with panic disorder and also with anxiety levels after caffeine administration in a gene--environment interactional model, will be discussed.	Caffeine	160-168	immunoglobulin kappa variable 2D-29	Homo sapiens	30-57
19019012-0	2009	A1 and A2a receptors mediate inhibitory effects of adenosine on the motor activity of human colon.	Adenosine	51-60	immunoglobulin kappa variable 2D-29	Homo sapiens	7-10
20021407-5	2009	Six antagonists, Bromocriptine, Cabergoline, Etilevodopa, Lysuride, Melevodopa and Pramipexole, were found more potent for binding and the active amino acids residues were identified (http://www.rcsb.org/pdb/) in A2A receptor.	Pramipexole	83-94	immunoglobulin kappa variable 2D-29	Homo sapiens	213-216
20021407-5	2009	Six antagonists, Bromocriptine, Cabergoline, Etilevodopa, Lysuride, Melevodopa and Pramipexole, were found more potent for binding and the active amino acids residues were identified (http://www.rcsb.org/pdb/) in A2A receptor.	Bromocriptine	17-30	immunoglobulin kappa variable 2D-29	Homo sapiens	213-216
20021407-5	2009	Six antagonists, Bromocriptine, Cabergoline, Etilevodopa, Lysuride, Melevodopa and Pramipexole, were found more potent for binding and the active amino acids residues were identified (http://www.rcsb.org/pdb/) in A2A receptor.	Cabergoline	32-43	immunoglobulin kappa variable 2D-29	Homo sapiens	213-216
20021407-5	2009	Six antagonists, Bromocriptine, Cabergoline, Etilevodopa, Lysuride, Melevodopa and Pramipexole, were found more potent for binding and the active amino acids residues were identified (http://www.rcsb.org/pdb/) in A2A receptor.	etilevodopa	45-56	immunoglobulin kappa variable 2D-29	Homo sapiens	213-216
20021407-5	2009	Six antagonists, Bromocriptine, Cabergoline, Etilevodopa, Lysuride, Melevodopa and Pramipexole, were found more potent for binding and the active amino acids residues were identified (http://www.rcsb.org/pdb/) in A2A receptor.	Lisuride	58-66	immunoglobulin kappa variable 2D-29	Homo sapiens	213-216
20021407-5	2009	Six antagonists, Bromocriptine, Cabergoline, Etilevodopa, Lysuride, Melevodopa and Pramipexole, were found more potent for binding and the active amino acids residues were identified (http://www.rcsb.org/pdb/) in A2A receptor.	levodopa methyl ester	68-78	immunoglobulin kappa variable 2D-29	Homo sapiens	213-216
19140664-0	2009	N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy.	n-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides	0-50	immunoglobulin kappa variable 2D-29	Homo sapiens	54-57
19140664-1	2009	In the present article, we report on a strategy to improve the physical properties of a series of small molecule human adenosine 2A (hA2A) antagonists.	Adenosine	119-128	immunoglobulin kappa variable 2D-29	Homo sapiens	133-137
19066414-1	2008	In the present study, the involvement of the selective adenosine A1 (CPA) and A2A (CGS 21680) and non-selective adenosine A1/A2A (NECA) receptor agonists on the development of hypersensitivity to acute morphine injection given during opiate withdrawal was investigated.	Morphine	202-210	immunoglobulin kappa variable 2D-29	Homo sapiens	98-128
18758473-1	2008	Adenosine is a key endogenous molecule that regulates tissue function by activating four G-protein-coupled adenosine receptors: A1, A2A, A2B and A3.	Adenosine	0-9	immunoglobulin kappa variable 2D-29	Homo sapiens	132-135
18249548-1	2008	A collection of 25 2-(2"-furyl)-1,2,4-triazolo[1,5-a]quinoxalines incorporating different substitution patterns at position 4 have been synthesized and their binding affinity towards human adenosine receptors (hA(1), hA(2A), hA(2B) and hA(3)) was determined.	2-(2"-furyl)-1,2,4-triazolo[1,5-a]quinoxalines	19-65	immunoglobulin kappa variable 2D-29	Homo sapiens	217-222
19356442-0	2008	Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.	regadenoson	102-113	immunoglobulin kappa variable 2D-29	Homo sapiens	90-93
18226909-1	2008	A large series of piperazin-, piperidin- and tetrahydroisoquinolinamides of 4-(1,3-dialkyl-9-deazaxanthin-8-yl)phenoxyacetic acid were prepared through conventional or multiple parallel syntheses and evaluated for their binding affinity at the recombinant human adenosine receptors, chiefly at the hA(2B) and hA(2A) receptor subtypes.	piperazin-, piperidin- and tetrahydroisoquinolinamides	18-72	immunoglobulin kappa variable 2D-29	Homo sapiens	309-315
18226909-4	2008	A number of selected ligands tested in functional assays in vitro showed very interesting antagonist activities and efficacies at both A(2A) and A(2B) receptor subtypes, with pA(2) values close to the corresponding pK(i)s. Structure-affinity and structure-selectivity relationships suggested that the binding potency at the hA(2B) receptor may be increased by lipophilic substituents at the N4-position of piperazinamides and that an ortho-methoxy substituent at the 8-phenyl ring and alkyl groups at N1 larger than the ones at N3, in the 9-deazaxanthine ring, may strongly enhance the hA(2A)/hA(2B) SI.	piperazinamides	406-421	immunoglobulin kappa variable 2D-29	Homo sapiens	135-140
18226909-4	2008	A number of selected ligands tested in functional assays in vitro showed very interesting antagonist activities and efficacies at both A(2A) and A(2B) receptor subtypes, with pA(2) values close to the corresponding pK(i)s. Structure-affinity and structure-selectivity relationships suggested that the binding potency at the hA(2B) receptor may be increased by lipophilic substituents at the N4-position of piperazinamides and that an ortho-methoxy substituent at the 8-phenyl ring and alkyl groups at N1 larger than the ones at N3, in the 9-deazaxanthine ring, may strongly enhance the hA(2A)/hA(2B) SI.	9-deazaxanthine	539-554	immunoglobulin kappa variable 2D-29	Homo sapiens	135-140
18215030-7	2008	Finally, 3D-QSAR and LBHM strategies have been utilized to predict the binding affinity of five new human A2A pyrazolo-triazolo-pyrimidine antagonists finding a good agreement between the theoretical and the experimental predictions.	Pyrazolotriazolopyrimidine	110-138	immunoglobulin kappa variable 2D-29	Homo sapiens	106-109
16765381-2	2006	Dual probe microdialysis was used to study A2A/D2 receptor interactions in the striato-pallidal GABA pathway in a model of Parkinson"s Disease.	gamma-Aminobutyric Acid	96-100	immunoglobulin kappa variable 2D-29	Homo sapiens	43-49
18307293-2	2008	Previously we have described a series of novel A 2A receptor antagonists with excellent water solubility.	Water	88-93	immunoglobulin kappa variable 2D-29	Homo sapiens	47-51
17310264-7	2007	SCH58261 was the most potent antagonist of the human A2A with a K(i) value of 4 nM, whereas Biogen-34 was the most potent antagonist of the rat A2A with a K(i) value of 1.2 nM.	5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine	0-8	immunoglobulin kappa variable 2D-29	Homo sapiens	53-56
16765381-8	2006	L-dopa induced dyskinesias could be caused by changes in the balance of A2A/D2 heteromers vs A2A homomers expressed at the surface membrane, where A2A homomers dominate with abnormal increases in A2A signaling.	Levodopa	0-6	immunoglobulin kappa variable 2D-29	Homo sapiens	72-78
15149696-3	2004	Based on the analysis of H-bond donor/acceptor capabilities of the isomeric triazolopyridine pairs it can be concluded that the H-bond donor strength of the free amino functionality is the main determinant for hA2a inhibitory activity and hA1 selectivity.	CP-808844	76-92	immunoglobulin kappa variable 2D-29	Homo sapiens	210-214
16867213-1	2006	Antagonism of the A2A adenosine function has proved beneficial in the treatment of Parkinson"s disease, in that it increases L-dopa therapeutical effects without concomitant worsening of its side-effects.	Adenosine	22-31	immunoglobulin kappa variable 2D-29	Homo sapiens	18-21
16867213-1	2006	Antagonism of the A2A adenosine function has proved beneficial in the treatment of Parkinson"s disease, in that it increases L-dopa therapeutical effects without concomitant worsening of its side-effects.	Levodopa	125-131	immunoglobulin kappa variable 2D-29	Homo sapiens	18-21
16867213-2	2006	In this paper we describe a preferential A2A adenosine antagonist, ST 1535, with long-lasting pharmacodynamic effects.	Adenosine	45-54	immunoglobulin kappa variable 2D-29	Homo sapiens	41-44
16867213-3	2006	It competitively antagonizes the effects of the A2A adenosine agonist NECA on cAMP in cells cloned with the human A2A adenosine receptor (IC50=353+/-30 nM), and the effects of the A1 adenosine agonist CHA on cAMP in cells cloned with the human A1 adenosine receptor (IC50=510+/-38 nM).	Cyclic AMP	78-82	immunoglobulin kappa variable 2D-29	Homo sapiens	48-51
16867213-3	2006	It competitively antagonizes the effects of the A2A adenosine agonist NECA on cAMP in cells cloned with the human A2A adenosine receptor (IC50=353+/-30 nM), and the effects of the A1 adenosine agonist CHA on cAMP in cells cloned with the human A1 adenosine receptor (IC50=510+/-38 nM).	Cyclic AMP	78-82	immunoglobulin kappa variable 2D-29	Homo sapiens	114-117
16867213-3	2006	It competitively antagonizes the effects of the A2A adenosine agonist NECA on cAMP in cells cloned with the human A2A adenosine receptor (IC50=353+/-30 nM), and the effects of the A1 adenosine agonist CHA on cAMP in cells cloned with the human A1 adenosine receptor (IC50=510+/-38 nM).	Adenosine	52-61	immunoglobulin kappa variable 2D-29	Homo sapiens	48-51
16867213-4	2006	ST 1535, at oral doses of 5 and 10 mg/kg, antagonizes catalepsy induced by intracerebroventricular administration of the A2A adenosine agonist CGS 21680 (10 microg/5 microl) in mice.	Adenosine	125-134	immunoglobulin kappa variable 2D-29	Homo sapiens	121-124
16867213-4	2006	ST 1535, at oral doses of 5 and 10 mg/kg, antagonizes catalepsy induced by intracerebroventricular administration of the A2A adenosine agonist CGS 21680 (10 microg/5 microl) in mice.	cysteinylglycine	143-146	immunoglobulin kappa variable 2D-29	Homo sapiens	121-124
16501051-6	2006	The inhibitory effects of CGS-21680 and histamine on PAF biosynthesis were prevented by the protein kinase A inhibitor H-89, supporting roles for the Gs -coupled receptors A2A and H2, respectively, and cyclic adenosine monophosphate in the inhibitory mechanism.	2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine	26-35	immunoglobulin kappa variable 2D-29	Homo sapiens	172-182
16501051-6	2006	The inhibitory effects of CGS-21680 and histamine on PAF biosynthesis were prevented by the protein kinase A inhibitor H-89, supporting roles for the Gs -coupled receptors A2A and H2, respectively, and cyclic adenosine monophosphate in the inhibitory mechanism.	Histamine	40-49	immunoglobulin kappa variable 2D-29	Homo sapiens	172-182
16501051-6	2006	The inhibitory effects of CGS-21680 and histamine on PAF biosynthesis were prevented by the protein kinase A inhibitor H-89, supporting roles for the Gs -coupled receptors A2A and H2, respectively, and cyclic adenosine monophosphate in the inhibitory mechanism.	Platelet Activating Factor	53-56	immunoglobulin kappa variable 2D-29	Homo sapiens	172-182
16501051-6	2006	The inhibitory effects of CGS-21680 and histamine on PAF biosynthesis were prevented by the protein kinase A inhibitor H-89, supporting roles for the Gs -coupled receptors A2A and H2, respectively, and cyclic adenosine monophosphate in the inhibitory mechanism.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	119-123	immunoglobulin kappa variable 2D-29	Homo sapiens	172-182
16353217-6	2006	In particular, discrepancies in mutational divergence between the Inuit populations and their putative source mtDNA pool in Siberia/Alaska for the two predominant haplotype clusters, A2a and A2b, are more consistent with the possibility that expanding Thule groups encountered and interbred with existing Dorset populations in Canada and Greenland.	thule	252-257	immunoglobulin kappa variable 2D-29	Homo sapiens	183-186
15294291-2	2004	The A2a-GFP protein was able to bind adenosine analogs indicating that the GFP tag did not alter the ligand binding activity of the receptor.	Adenosine	37-46	immunoglobulin kappa variable 2D-29	Homo sapiens	4-7
14663020-0	2003	Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson"s disease.	istradefylline	100-106	immunoglobulin kappa variable 2D-29	Homo sapiens	35-38
11592813-6	2001	The receptors that transduce adenosine action include A1, A2a, A2b, and A3 adenosine receptors.	Adenosine	29-38	immunoglobulin kappa variable 2D-29	Homo sapiens	58-61
12671949-1	2003	Piribedil is a non-ergot D2/D3 agonist with a significant antagonist action on alpha2A and alpha2C adrenergic receptor subtypes.	Piribedil	0-9	immunoglobulin kappa variable 2D-29	Homo sapiens	79-86
11739107-3	2002	The A(2A) adenosine receptor (A(2A)-AR) is a member of the family of guanine nucleotide binding proteins and has become a focus of major interest primarily because of its ability to broadly inactivate the inflammatory cascade.	Guanine Nucleotides	69-87	immunoglobulin kappa variable 2D-29	Homo sapiens	30-38
11906291-4	2002	1,8-disubstituted xanthine derivatives were equipotent to or more potent than 1,3,8-trisubstituted xanthines at A2B ARs, but generally less potent at A1 and A2A, and much less potent at A3 ARs.	1,8-disubstituted xanthine	0-26	immunoglobulin kappa variable 2D-29	Homo sapiens	157-160
11906291-10	2002	1-Butyl-8-p-carboxyphenylxanthine (10), another polar analogue bearing a carboxylate function, exhibited a K(i) value of 24 nM for A2B ARs, 49-fold selectivity versus human and 20-fold selectivity versus rat A1 ARs, and greater than 150-fold selectivity versus human A2A and A3 ARs.	1-butyl-8-p-carboxyphenylxanthine	0-33	immunoglobulin kappa variable 2D-29	Homo sapiens	267-270
11296702-1	2001	On the basis of earlier suggested unitary mechanism of synaptic plasticity opposite effects of adenosine and dopamine on the cAMP concentration in striatal spinal cells can emphasize the well known antagonistic interactions between A2A and D2 receptors on striatopallidal cells and between A1 and D1 receptors on striatonigral cells.	Adenosine	95-104	immunoglobulin kappa variable 2D-29	Homo sapiens	232-242
11296702-1	2001	On the basis of earlier suggested unitary mechanism of synaptic plasticity opposite effects of adenosine and dopamine on the cAMP concentration in striatal spinal cells can emphasize the well known antagonistic interactions between A2A and D2 receptors on striatopallidal cells and between A1 and D1 receptors on striatonigral cells.	Dopamine	109-117	immunoglobulin kappa variable 2D-29	Homo sapiens	232-242
11296702-1	2001	On the basis of earlier suggested unitary mechanism of synaptic plasticity opposite effects of adenosine and dopamine on the cAMP concentration in striatal spinal cells can emphasize the well known antagonistic interactions between A2A and D2 receptors on striatopallidal cells and between A1 and D1 receptors on striatonigral cells.	Cyclic AMP	125-129	immunoglobulin kappa variable 2D-29	Homo sapiens	232-242
8750371-4	1995	Plasma antifactor IIa (aIIa) activity levels after the 30- and 60-U/kg doses of ardeparin were too low to reliably characterize the disposition of the drug.	ardeparin	80-89	immunoglobulin kappa variable 2D-29	Homo sapiens	23-27
9914161-2	1999	Many of the adenosine actions seem to be mediated by specific surface receptors positively coupled to adenylate cyclase: A2A and A2B.	Adenosine	12-21	immunoglobulin kappa variable 2D-29	Homo sapiens	121-132
9756374-8	1998	Small but statistically significant inhibitions of the adenosine-(50 microM)-stimulated increase in chloride efflux were elicited by the A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (CPX, 100 nM) and the A2 receptor antagonist 3,7-dimethyl-1-propylargylxanthine (DMPX, 10 microM).	Adenosine	55-64	immunoglobulin kappa variable 2D-29	Homo sapiens	217-219
9756374-8	1998	Small but statistically significant inhibitions of the adenosine-(50 microM)-stimulated increase in chloride efflux were elicited by the A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (CPX, 100 nM) and the A2 receptor antagonist 3,7-dimethyl-1-propylargylxanthine (DMPX, 10 microM).	Chlorides	100-108	immunoglobulin kappa variable 2D-29	Homo sapiens	217-219
9756374-8	1998	Small but statistically significant inhibitions of the adenosine-(50 microM)-stimulated increase in chloride efflux were elicited by the A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (CPX, 100 nM) and the A2 receptor antagonist 3,7-dimethyl-1-propylargylxanthine (DMPX, 10 microM).	1,3-dipropyl-8-cyclopentylxanthine	196-199	immunoglobulin kappa variable 2D-29	Homo sapiens	217-219
9453355-7	1998	Both KF17837 (selective A2 antagonist) and DPSPX (A1/A2 antagonist), but not DPCPX (selective A1 antagonist), blocked the antimitogenic effects of 2-chloroadenosine, EHNA, and dipyridamole on DNA and collagen synthesis, suggesting the involvement of A2A and/or A2B, but excluding the participation of A1, receptors.	KF 17837	5-12	immunoglobulin kappa variable 2D-29	Homo sapiens	250-253
9453355-7	1998	Both KF17837 (selective A2 antagonist) and DPSPX (A1/A2 antagonist), but not DPCPX (selective A1 antagonist), blocked the antimitogenic effects of 2-chloroadenosine, EHNA, and dipyridamole on DNA and collagen synthesis, suggesting the involvement of A2A and/or A2B, but excluding the participation of A1, receptors.	1,3-dipropyl-8-(4-sulfophenyl)xanthine	43-48	immunoglobulin kappa variable 2D-29	Homo sapiens	250-253
10714510-1	2000	A series of N6,2-disubstituted adenosine analogues have been synthesized and their functional activity measured against A2a and A1 receptors.	n6,2-disubstituted adenosine	12-40	immunoglobulin kappa variable 2D-29	Homo sapiens	120-123
1851342-1	1991	In six healthy volunteers we have estimated the pharmacokinetic parameters of the anti factor Xa (AXa) and anti factor IIa (AIIa) activities of a LMW heparin, Logiparin.	Heparin, Low-Molecular-Weight	146-157	immunoglobulin kappa variable 2D-29	Homo sapiens	124-128
7739005-0	1995	2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5"-N-ethyluronamide as selective A2a adenosine receptor agonists.	2-aralkynyl	0-11	immunoglobulin kappa variable 2D-29	Homo sapiens	90-93
7739005-0	1995	2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5"-N-ethyluronamide as selective A2a adenosine receptor agonists.	2-heteroalkynyl	16-31	immunoglobulin kappa variable 2D-29	Homo sapiens	90-93
7739005-0	1995	2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5"-N-ethyluronamide as selective A2a adenosine receptor agonists.	Adenosine-5'-(N-ethylcarboxamide)	47-76	immunoglobulin kappa variable 2D-29	Homo sapiens	90-93
7739005-8	1995	From these data and those previously reported, the structure-activity relationships derived for the 2-alkynyl-substituted ribose uronamides would indicate that potentiation of A2a receptor affinity could be obtained by aromatic rings not conjugated with the triple bond or by heteroaromatic groups.	2-alkynyl-substituted ribose uronamides	100-139	immunoglobulin kappa variable 2D-29	Homo sapiens	176-179
7731018-1	1995	Synthesis and A1 and A2a adenosine binding activities of some 1-aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3-c] pyrazol-4-ones, 1-aryl-4,9-dihydro-3-methyl-1H-pyrazolo[3,4-b]quinolin-4- ones, and 1-aryl-1H-imidazo[4,5-b]quinoxalines.	Adenosine	25-34	immunoglobulin kappa variable 2D-29	Homo sapiens	21-24
7731018-1	1995	Synthesis and A1 and A2a adenosine binding activities of some 1-aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3-c] pyrazol-4-ones, 1-aryl-4,9-dihydro-3-methyl-1H-pyrazolo[3,4-b]quinolin-4- ones, and 1-aryl-1H-imidazo[4,5-b]quinoxalines.	1-aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3-c] pyrazol-4-ones	62-125	immunoglobulin kappa variable 2D-29	Homo sapiens	21-24
7731018-1	1995	Synthesis and A1 and A2a adenosine binding activities of some 1-aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3-c] pyrazol-4-ones, 1-aryl-4,9-dihydro-3-methyl-1H-pyrazolo[3,4-b]quinolin-4- ones, and 1-aryl-1H-imidazo[4,5-b]quinoxalines.	1-aryl-4,9-dihydro-3-methyl-1h-pyrazolo[3,4-b]quinolin-4- ones	127-189	immunoglobulin kappa variable 2D-29	Homo sapiens	21-24
7731018-2	1995	The syntheses and A1 and A2a adenosine binding activities of some new 1-aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3-c]pyrazol-4-ones, 1-aryl-4,9-dihydro-3-methyl-1H-pyrazolo[3,4-b]-quinolin-4-ones, and 1-aryl-1H-imidazo[4,5-b]quinoxalines are reported.	Adenosine	29-38	immunoglobulin kappa variable 2D-29	Homo sapiens	25-28
7731018-2	1995	The syntheses and A1 and A2a adenosine binding activities of some new 1-aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3-c]pyrazol-4-ones, 1-aryl-4,9-dihydro-3-methyl-1H-pyrazolo[3,4-b]-quinolin-4-ones, and 1-aryl-1H-imidazo[4,5-b]quinoxalines are reported.	1-aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3-c]pyrazol-4-ones	70-132	immunoglobulin kappa variable 2D-29	Homo sapiens	25-28
7731018-2	1995	The syntheses and A1 and A2a adenosine binding activities of some new 1-aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3-c]pyrazol-4-ones, 1-aryl-4,9-dihydro-3-methyl-1H-pyrazolo[3,4-b]-quinolin-4-ones, and 1-aryl-1H-imidazo[4,5-b]quinoxalines are reported.	1-aryl-4,9-dihydro-3-methyl-1h-pyrazolo[3,4-b]-quinolin-4-ones	134-196	immunoglobulin kappa variable 2D-29	Homo sapiens	25-28
7731018-2	1995	The syntheses and A1 and A2a adenosine binding activities of some new 1-aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3-c]pyrazol-4-ones, 1-aryl-4,9-dihydro-3-methyl-1H-pyrazolo[3,4-b]-quinolin-4-ones, and 1-aryl-1H-imidazo[4,5-b]quinoxalines are reported.	1-aryl-1h-imidazo[4,5-b]quinoxalines	202-238	immunoglobulin kappa variable 2D-29	Homo sapiens	25-28
1851342-1	1991	In six healthy volunteers we have estimated the pharmacokinetic parameters of the anti factor Xa (AXa) and anti factor IIa (AIIa) activities of a LMW heparin, Logiparin.	Logiparin	159-168	immunoglobulin kappa variable 2D-29	Homo sapiens	124-128
34319736-6	2021	For the first time, falcarinol (1a) and its analogue (R)-2i were found to have potential L-type calcium channel-blocking activity, as recorded using a manual patch clamp technique on HEK-293 cells stably expressing hCav1.2 (alpha1C/beta2a/alpha2delta1).	falcarinol	20-30	immunoglobulin kappa variable 2D-29	Homo sapiens	232-251
33235193-1	2020	Adenosine, its interacting A1 and A2A receptors, and particularly the variant rs5751876 in the A2A gene ADORA2A have been shown to modulate anxiety, arousal, and sleep.	Adenosine	0-9	immunoglobulin kappa variable 2D-29	Homo sapiens	95-98
15104468-0	2004	Efficient synthesis of an adenosine A2a agonist: glycosylation of 2-haloadenines and an N2-alkyl-6-chloroguanine.	2-haloadenines	66-80	immunoglobulin kappa variable 2D-29	Homo sapiens	36-39
15104468-0	2004	Efficient synthesis of an adenosine A2a agonist: glycosylation of 2-haloadenines and an N2-alkyl-6-chloroguanine.	n2-alkyl-6-chloroguanine	88-112	immunoglobulin kappa variable 2D-29	Homo sapiens	36-39
15104468-1	2004	A convergent synthesis of adenosine A2a agonist 1 in the form of its maleate salt 2 was achieved.	maleate salt	69-81	immunoglobulin kappa variable 2D-29	Homo sapiens	36-39
24687255-3	2014	Among new classes of drugs, adenosine A2A antagonists have emerged as promising candidates.	Adenosine	28-37	immunoglobulin kappa variable 2D-29	Homo sapiens	38-41
24687255-5	2014	To date, the clinical research regarding A2A antagonists and their potential utilization in PD therapy continues to evolve between drugs just or previously discontinued (preladenant and vipadenant), new derivatives in development (tozadenant, PBF-509, ST1535, ST4206 and V81444) and the relatively old drug istradefylline, which has finally been licensed as an anti-parkinsonian drug in Japan.	istradefylline	307-321	immunoglobulin kappa variable 2D-29	Homo sapiens	41-44
24687255-7	2014	Moreover, results from phase II and III trials also demonstrate that A2A antagonists are effective in reducing off-time, without worsening troublesome dyskinesia, and in increasing on-time with a mild increase of non-troublesome dyskinesia, in patients at an advanced stage of PD treated with L-DOPA.	Levodopa	293-299	immunoglobulin kappa variable 2D-29	Homo sapiens	69-72
35224877-6	2022	BRL44408 was the most alpha2A-selective antagonist, although its alpha1A-affinity (81 nM) is only 9-fold greater than its alpha2C-affinity.	BRL 44408	0-8	immunoglobulin kappa variable 2D-29	Homo sapiens	22-29
35569686-0	2022	2,3-Dihydrobenzo-dioxine piperidine derivatives as potent and selective alpha2c antagonists.	2,3-dihydrobenzo-dioxine piperidine	0-35	immunoglobulin kappa variable 2D-29	Homo sapiens	72-79
35569686-1	2022	In this manuscript, we report a series of benzodioxine methyl piperidine derivatives as highly potent and selective alpha2C antagonists by ligand design to improve the pharmacokinetics of a previous candidate molecule.	benzodioxine	42-54	immunoglobulin kappa variable 2D-29	Homo sapiens	116-123
35569686-1	2022	In this manuscript, we report a series of benzodioxine methyl piperidine derivatives as highly potent and selective alpha2C antagonists by ligand design to improve the pharmacokinetics of a previous candidate molecule.	methyl piperidine	55-72	immunoglobulin kappa variable 2D-29	Homo sapiens	116-123
35199177-8	2022	Chlormethine gel was given as monotherapy in 12 patients (52.17%), and in addition to systemic treatments (methotrexate and peginterferon alpha-2a) in 11 patients (47.82%).	Mechlorethamine	0-12	immunoglobulin kappa variable 2D-29	Homo sapiens	138-146
35224877-7	2022	MK-912 is the highest-affinity, most alpha2C-selective antagonist (0.15 nM alpha2C-affinity) although its alpha2C-selectivity is only 13-fold greater than at alpha2A.	L 657743	0-6	immunoglobulin kappa variable 2D-29	Homo sapiens	37-44
35224877-7	2022	MK-912 is the highest-affinity, most alpha2C-selective antagonist (0.15 nM alpha2C-affinity) although its alpha2C-selectivity is only 13-fold greater than at alpha2A.	L 657743	0-6	immunoglobulin kappa variable 2D-29	Homo sapiens	75-82
35224877-7	2022	MK-912 is the highest-affinity, most alpha2C-selective antagonist (0.15 nM alpha2C-affinity) although its alpha2C-selectivity is only 13-fold greater than at alpha2A.	L 657743	0-6	immunoglobulin kappa variable 2D-29	Homo sapiens	106-113
35464557-2	2022	On the other hand, dexmedetomidine is highly selective and has a greater affinity toward alpha2 adrenergic receptors, especially toward its alpha2a subtype, accountable for more analgesic and hypnotic effects than clonidine.	Dexmedetomidine	19-34	immunoglobulin kappa variable 2D-29	Homo sapiens	140-147
2847169-5	1988	When 2-(2-methoxyethoxy)ethyl 8-(cis-2-n-octylcyclopropyl)octanoate (A2C) was added to each fraction, Na+,K+-ATPase, but not glucagon-stimulated adenylate cyclase activity, was activated in the apical fraction.	2-(2-methoxyethoxy)ethyl 8-(cis-2-n-octylcyclopropyl)octanoate	5-67	immunoglobulin kappa variable 2D-29	Homo sapiens	69-72
35224877-4	2022	Here, 3 H-rauwolscine whole cell binding was used to determine the affinity and selectivity of 99 alpha-antagonists (including antidepressants and antipsychotics) in CHO cells expressing human alpha2A, alpha2B, or alpha2C-adrenoceptors, using an identical method to beta and alpha1-adrenoceptor measurements, thus allowing direct human receptor comparisons.	h-rauwolscine	8-21	immunoglobulin kappa variable 2D-29	Homo sapiens	193-200
35224877-4	2022	Here, 3 H-rauwolscine whole cell binding was used to determine the affinity and selectivity of 99 alpha-antagonists (including antidepressants and antipsychotics) in CHO cells expressing human alpha2A, alpha2B, or alpha2C-adrenoceptors, using an identical method to beta and alpha1-adrenoceptor measurements, thus allowing direct human receptor comparisons.	h-rauwolscine	8-21	immunoglobulin kappa variable 2D-29	Homo sapiens	214-221
1005114-1	1976	Under the conditions that RNA ligase converts the tetranucleotide, pA-A2-A, to larger polynucleotides, no such polymerization can be detected with the derivative, pA-A2-A(MeOEt), that possesses a terminal 2"-0-(alpha-methoxyethyl) group.	tetranucleotide	50-65	immunoglobulin kappa variable 2D-29	Homo sapiens	70-74
1005114-1	1976	Under the conditions that RNA ligase converts the tetranucleotide, pA-A2-A, to larger polynucleotides, no such polymerization can be detected with the derivative, pA-A2-A(MeOEt), that possesses a terminal 2"-0-(alpha-methoxyethyl) group.	Polynucleotides	86-101	immunoglobulin kappa variable 2D-29	Homo sapiens	70-74
1005114-3	1976	Thus, the enzyme, together with ATP, converts equimolar quantities of A-A2-A and pA-A2-A(MeOEt) to A-A6-A(MeOEt) in 55% yield, while a similar reaction with A-A2-A and pU-U2-U(MeOEt) results in a 40% yield of A-A3-U3-U(MeOEt).	Adenosine Triphosphate	32-35	immunoglobulin kappa variable 2D-29	Homo sapiens	72-76
1005114-3	1976	Thus, the enzyme, together with ATP, converts equimolar quantities of A-A2-A and pA-A2-A(MeOEt) to A-A6-A(MeOEt) in 55% yield, while a similar reaction with A-A2-A and pU-U2-U(MeOEt) results in a 40% yield of A-A3-U3-U(MeOEt).	Adenosine Triphosphate	32-35	immunoglobulin kappa variable 2D-29	Homo sapiens	84-88
1005114-3	1976	Thus, the enzyme, together with ATP, converts equimolar quantities of A-A2-A and pA-A2-A(MeOEt) to A-A6-A(MeOEt) in 55% yield, while a similar reaction with A-A2-A and pU-U2-U(MeOEt) results in a 40% yield of A-A3-U3-U(MeOEt).	Adenosine Triphosphate	32-35	immunoglobulin kappa variable 2D-29	Homo sapiens	84-88
1005114-9	1976	The terminal 3"-phosphate group serves equally well as a blocking group for specific ligation reactions in that the ligase converts equimolar amounts of A-A2-A and pA-A2-Ap to A-A6-Ap in 50% yield.	3"-phosphate	13-25	immunoglobulin kappa variable 2D-29	Homo sapiens	155-159
1005114-9	1976	The terminal 3"-phosphate group serves equally well as a blocking group for specific ligation reactions in that the ligase converts equimolar amounts of A-A2-A and pA-A2-Ap to A-A6-Ap in 50% yield.	3"-phosphate	13-25	immunoglobulin kappa variable 2D-29	Homo sapiens	167-172
1005114-9	1976	The terminal 3"-phosphate group serves equally well as a blocking group for specific ligation reactions in that the ligase converts equimolar amounts of A-A2-A and pA-A2-Ap to A-A6-Ap in 50% yield.	a-a6-ap	176-183	immunoglobulin kappa variable 2D-29	Homo sapiens	155-159
1005114-9	1976	The terminal 3"-phosphate group serves equally well as a blocking group for specific ligation reactions in that the ligase converts equimolar amounts of A-A2-A and pA-A2-Ap to A-A6-Ap in 50% yield.	a-a6-ap	176-183	immunoglobulin kappa variable 2D-29	Homo sapiens	167-172
33834710-8	2021	Brexpiprazole is a highly affine (potent) alpha2C antagonist and, therefore, also an indirect 5-HT1A agonist.	brexpiprazole	0-13	immunoglobulin kappa variable 2D-29	Homo sapiens	42-49
32837981-6	2020	Further analysis demonstrated that the variation of the S protein at site 614 (QHD43416.1: p.614D>G) was a characteristic of stains in Clades A2 and A2a.	qhd43416	79-87	immunoglobulin kappa variable 2D-29	Homo sapiens	149-152
32722122-3	2020	Herein, we report on the synthesis and biological evaluation of a new set of piperazine- and piperidine- containing 7-amino-2-(furan-2-yl)thiazolo[5,4-d]pyrimidine derivatives designed as human A2A AR antagonists/inverse agonists.	Piperazine	77-87	immunoglobulin kappa variable 2D-29	Homo sapiens	194-197
32722122-3	2020	Herein, we report on the synthesis and biological evaluation of a new set of piperazine- and piperidine- containing 7-amino-2-(furan-2-yl)thiazolo[5,4-d]pyrimidine derivatives designed as human A2A AR antagonists/inverse agonists.	piperidine	93-103	immunoglobulin kappa variable 2D-29	Homo sapiens	194-197
32722122-3	2020	Herein, we report on the synthesis and biological evaluation of a new set of piperazine- and piperidine- containing 7-amino-2-(furan-2-yl)thiazolo[5,4-d]pyrimidine derivatives designed as human A2A AR antagonists/inverse agonists.	7-amino-2-(furan-2-yl)thiazolo[5,4-d]pyrimidine	116-163	immunoglobulin kappa variable 2D-29	Homo sapiens	194-197
32722122-5	2020	Amongst them, the 2-(furan-2-yl)-N5-(2-(4-phenylpiperazin-1-yl)ethyl)thiazolo[5,4-d]pyrimidine-5,7-diamine 11 exhibited the highest A2A AR binding affinity (Ki = 8.62 nM) as well as inverse agonist potency (IC50 = 7.42 nM).	2-(furan-2-yl)-n5-(2-(4-phenylpiperazin-1-yl)ethyl)thiazolo[5,4-d]pyrimidine-5,7-diamine	18-106	immunoglobulin kappa variable 2D-29	Homo sapiens	132-135
32764876-5	2020	Despite its approval, the clinical use of danoprevir is currently limited to its combination with peginterferon alpha-2a and ribavirin, thereby driving its development towards interferon-free, ribavirin-free regimens with improved tolerability and adherence.	danoprevir	42-52	immunoglobulin kappa variable 2D-29	Homo sapiens	112-120
32015389-6	2020	DARC identifies, as functionally-congruent features linking allosterically the ATP, DNA, and clamp binding sites: residues distinctive of gamma and of gamma/delta" that mutually interact in trans, centered on the catalytic base; several gamma/delta"-residues and six gamma/delta"-covariant residue pairs within the DNA binding N-termini of helices alpha2 and alpha3; and gamma/delta"-residues associated with the alpha2 C-terminus and the clamp-binding loop.	Adenosine Triphosphate	79-82	immunoglobulin kappa variable 2D-29	Homo sapiens	413-421
32764876-3	2020	Adverse events such as anemia, fatigue, fever, and headache were associated with the inclusion of peginterferon alpha-2a and ribavirin in the danoprevir-based regimen.	danoprevir	142-152	immunoglobulin kappa variable 2D-29	Homo sapiens	112-120
32256718-2	2020	Dexmedetomidine is clinically effective by acting on alpha2 adrenergic receptor and the impact of the adrenoceptor alpha2A gene (ADRA2A) polymorphisms on the anesthetic and analgesic effects of dexmedetomidine is related to the clinical application of dexmedetomidine.	Dexmedetomidine	194-209	immunoglobulin kappa variable 2D-29	Homo sapiens	115-122
31689542-2	2020	The aim of this study was to evaluate the effect of the de novo combination therapy including pegylated-interferon alpha-2a (PEG-IFNalpha-2a) and entecavir (ETV) in this high risk population.	Polyethylene Glycols	125-128	immunoglobulin kappa variable 2D-29	Homo sapiens	115-123
31578448-0	2019	Reconstruction of apo A2A receptor activation pathways reveal ligand-competent intermediates and state-dependent cholesterol hotspots.	Cholesterol	113-124	immunoglobulin kappa variable 2D-29	Homo sapiens	22-25
31578448-6	2019	Here, we reconstruct the activation pathways of the apo adenosine receptor (A2A), starting from an inactive conformation, by applying adaptive sampling MD combined with a goal-oriented scoring function.	Adenosine	56-65	immunoglobulin kappa variable 2D-29	Homo sapiens	76-79
31578448-8	2019	Exploration of the apo conformational landscape of A2A reveals the existence of ligand-competent states, active intermediates and state-dependent cholesterol hotspots of relevance for drug discovery.	Cholesterol	146-157	immunoglobulin kappa variable 2D-29	Homo sapiens	51-54
31009638-2	2019	In this study, we examined the inhibitory effect of guanabenz, a centrally acting alpha2-adrenoceptor agonist with high specificity for alpha2A-subtype, on HCN channels in mesencephalic trigeminal nucleus (MTN) neurons which robustly express HCN channels and have been suggested to coexpress alpha2A-adrenoceptors.	Guanabenz	52-61	immunoglobulin kappa variable 2D-29	Homo sapiens	136-143
30913470-2	2019	In this work, an enlarged series of 1,2,4-triazolo[4,3-a]pyrazin-3-ones was designed to target the human (h) A2A adenosine receptor (AR) or both hA1 and hA2A ARs.	1,2,4-triazolo[4,3-a]pyrazin-3-ones	36-71	immunoglobulin kappa variable 2D-29	Homo sapiens	109-112
30913470-2	2019	In this work, an enlarged series of 1,2,4-triazolo[4,3-a]pyrazin-3-ones was designed to target the human (h) A2A adenosine receptor (AR) or both hA1 and hA2A ARs.	1,2,4-triazolo[4,3-a]pyrazin-3-ones	36-71	immunoglobulin kappa variable 2D-29	Homo sapiens	153-157
30657666-3	2019	Here, we report the development, chemical synthesis, and biological screening of a compound library that led to the identification of the beta2c- and beta2i-selective compounds LU-002c (4; IC50 beta2c: 8 nM, IC50 beta2i/beta2c: 40-fold) and LU-002i (5; IC50 beta2i: 220 nM, IC50 beta2c/beta2i: 45-fold), respectively.	lu-002c	177-184	immunoglobulin kappa variable 2D-29	Homo sapiens	138-144
30657666-3	2019	Here, we report the development, chemical synthesis, and biological screening of a compound library that led to the identification of the beta2c- and beta2i-selective compounds LU-002c (4; IC50 beta2c: 8 nM, IC50 beta2i/beta2c: 40-fold) and LU-002i (5; IC50 beta2i: 220 nM, IC50 beta2c/beta2i: 45-fold), respectively.	lu-002c	177-184	immunoglobulin kappa variable 2D-29	Homo sapiens	194-200
30657666-3	2019	Here, we report the development, chemical synthesis, and biological screening of a compound library that led to the identification of the beta2c- and beta2i-selective compounds LU-002c (4; IC50 beta2c: 8 nM, IC50 beta2i/beta2c: 40-fold) and LU-002i (5; IC50 beta2i: 220 nM, IC50 beta2c/beta2i: 45-fold), respectively.	lu-002c	177-184	immunoglobulin kappa variable 2D-29	Homo sapiens	194-200
30657666-3	2019	Here, we report the development, chemical synthesis, and biological screening of a compound library that led to the identification of the beta2c- and beta2i-selective compounds LU-002c (4; IC50 beta2c: 8 nM, IC50 beta2i/beta2c: 40-fold) and LU-002i (5; IC50 beta2i: 220 nM, IC50 beta2c/beta2i: 45-fold), respectively.	lu-002i	241-248	immunoglobulin kappa variable 2D-29	Homo sapiens	138-144
30198788-4	2019	MATERIAL AND METHODS: The human Muller cell line MIO-M1 was treated with the alpha2A-ADR agonist brimonidine in combination with inhibitors for Src-kinase, EGFR-kinase, matrix metalloproteinase (MMP) as well as small interfering RNAs (siRNAs) for the EGFR.	Brimonidine Tartrate	97-108	immunoglobulin kappa variable 2D-29	Homo sapiens	77-84
30198788-6	2019	RESULTS: Our results show that human MIO-M1 cells express alpha2A-ADRs and that stimulation of these receptors caused a robust increase of ERK1/2 and protein kinase B (PKB/AKT) (Thr-308) phosphorylation in MIO-M1 cells.	Threonine	178-181	immunoglobulin kappa variable 2D-29	Homo sapiens	58-65
30380560-0	2019	Tetanic Facilitation of Neuromuscular Transmission by Adenosine A2A and Muscarinic M1 Receptors is Dependent on the Uptake of Choline via High-Affinity Transporters.	Choline	126-133	immunoglobulin kappa variable 2D-29	Homo sapiens	64-95